In this context, our research aimed at evaluating the effect of metformin as an adjuvant therapy to aromatase inhibitor (letrozole) on estradiol and other biomarkers involved in the pathogenesis of breast cancer in overweight and obese postmenopausal women. The gene discussed is CYP19A1; the disease is breast carcinoma.